On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has swung higher to the tune of almost 8%. Interestingly, Friday’s afterhours ...

In this video, Suzanne E. Schindler, MD, PhD, discusses the efficacy of both lecanemab (Leqembi, Eisai) and donanemab (Kisunla, Eli Lilly & Co.) for the treatment of Alzheimer’s disease, presented at ...